Clinical trial indicates sulthiame, an epilepsy drug, may reduce obstructive sleep apnea symptoms.

A recent clinical trial suggests that sulthiame, an epilepsy drug used in Europe, may effectively reduce symptoms of obstructive sleep apnea (OSA), impacting about 5% of the population. The study of 298 patients showed a reduction in breathing interruptions and improved oxygen levels, with symptom reduction of up to 50%. While promising, further research is necessary to confirm long-term effects and potential side effects before broader adoption as a treatment.

September 10, 2024
49 Articles